After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex ...
Sionna Therapeutics, a biopharmaceutical company dedicated to advancing treatments for cystic fibrosis (CF), has significantly strengthened its position in the CF therapeutic landscape through a ...
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics (SION), Inc. , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...
Sionna Therapeutics has quickly found a use for some of its $182 million series C haul, inking a deal with AbbVie to add three clinical-phase candidates to its burgeoning pipeline of cystic fibrosis ...
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy ...
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...
Following these transactions, the involved parties now hold a total of 6,684,962 shares of Sionna Therapeutics' common stock. This strategic move reflects TPG's continued interest and investment in ...
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback